Pituitary Adenomas – Clinico-Pathological, Immunohistochemical and Ultrastructural Study by Alma Ortiz-Plata et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
4 
Pituitary Adenomas – Clinico-Pathological, 
Immunohistochemical and Ultrastructural Study 
Alma Ortiz-Plata, Martha L. Tena-Suck, Iván Pérez-Neri,  
Daniel Rembao-Bojórquez and Angeles Fernández  
National Institute of Neurology and Neurosurgery 
México City 
México 
1. Introduction  
Pituitary adenomas (PA) constitute about 10% of intracranial neoplasm. Most of them have 
its origin in adenohypophysis (Cury et al., 2009; Rosai, 1989). They occur most often in 
adults between the ages of 30 and 60 years, and may have slightly higher incidence in 
females in early life (20-45 years) and in males in later life (35-60 years) (Davis et al., 2001; 
McDowell et al., 2011). The majority of pituitary adenomas have a sporadic origin; familial 
cases represent 5% of all pituitary tumors (Vandeva et al., 2010; Tichomirowa et al., 2009). 
Couldwell and Cannon (2010) report strong evidence of genetic contribution for 
predisposition to symptomatic pituitary tumors.  
Pituitary adenomas clinically manifest by signs of hypopituitarism, this is caused by the 
compression of the gland by the tumor which may affect fertility, the compression of other 
adjacent structures may cause headache and if the optic chiasm is affected visual alterations; 
secretion of one or more specific hormones can take place (Galland & Chanson, 2009; 
Melmed, 2010). However, up to 30% of adenomas do not secrete hormones (Cury et al., 
2009; Martinez, 1986; Moreno, 2005). 
Pituitary adenomas have been classified as: microadenomas (<10mm diameter) and 
macroadenomas (> 10 mm diameter), according to its size assessed by tomography and 
magnetic resonance; staining affinity (acidophilic, chromophobic or basophilic); hormonal 
activity or secretion of growth hormone (GH), prolactin (PRL), thyroid stimulating 
hormone(TSH), adrenocorticotrophin hormone (ACTH), follicle stimulating hormone (FSH), 
and luteinizing hormone (LH); and ultrastructural characteristics (Galland & Chanson, 2009; 
Nosé, 2011). Hardy (1973) classified pituitary adenomas in four grades according to its size 
and local invasion degree: 
Grade I: Microadenomas, measuring less than 10mm in diameter, they minimally alter the 
radiographic appearance of the sella. 
Grade II: Macroadenomas are bigger than 10mm in diameter, they enlarge the sella or 
exhibit suprasellar expansion, but not cause destruction. 
Grade III: Invasive adenomas, locally eroded the sella, and show suprasellar outgrowth. 
Grade IV: Strongly invasive adenomas, that destroys adjacent bony structures and with 
suprasellar outgrowth, including bone, hypothalamus, and the cavernous sinus. 
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This classification remains valid using computed tomography scanning and magnetic 
resonance imaging. 
Histologically pituitary adenomas are dense cellular tumors, composed by cells with solid 
nuclei, rounded and uniform. These cells can be arranged in big groups (diffused pattern), 
around sinusoidal vessels (sinusoidal pattern), or covering connective-vascular axes 
(papillary pattern). In all PA types, atypia and mitotic cells are rare. Despite the 
histologically benign aspect, pituitary adenomas may have an invasive behavior (Chang, 
2010; Lau, et al., 2010; Li-Ng, 2008; Melmed, 2010; Scheithauer, 1986; Zada et al., 2011;). This 
factor is not necessarily indicative of malignancy, because tumor growth is slow and 
metastases are rare. The histological aspect is not different from the rare carcinoma cases 
(Colao et al., 2010; Crocker, 1978; Kaltsas et al., 2005; Schteithauer et al., 2005; Tena-Suck et 
al., 2006;). 
In most patients the pathologist cannot provide information about the PA behavior, if will 
be aggressive based on the histological appearance of adenomas, this is because tumors with 
variations in the size, shape and nuclear density and the presence of bi-or multinucleated 
cells do not necessarily had a poor prognosis.  
The functional classification of pituitary adenomas based on its hormonal activity, assessed 
by immunohistochemistry technique, and associated with the transmission electron 
microscopy analysis, has allowed the characterization of neoplastic cells in detail and 
proposes the classification of the adenomas in 14 different types, this allows a better 
correlation with the clinical manifestations that the old classification of chromophobe, 
acidophilic and basophilic pituitary adenomas (Horvath & Kovacs, 1992; Horvath, 1994; 
Kovacs & Horvath, 1986). 
The aim of this investigation is to present a review of different cases of pituitary adenomas 
studied in the Laboratory of Experimental Neuropathology of National Institute of 
Neurology and Neurosurgery, correlating the local invasion degree, clinical manifestations, 
histological aspects, immunohistochemical and ultrastructural features, with  the biological 
behavior, especially with the invasive potential. 
2. Methods  
One hundred and twenty two cases of pituitary adenomas were studied. They were 
classified by their local invasion degree according with Hardy classification (Hardy, 1973), 
endocrine symptoms (clinically functioning and clinically non functioning pituitary 
adenomas) and by their hormonal secretion, assessed by immunohistochemistry. The 
evolution of the disease at the time of diagnosis, tumor regrowth, bromocriptine treatment, 
and time of outcome of the patients, were evaluated to analyze the PA biological behavior. 
2.1 Histopathological analysis  
The biopsies were divided in two parts; the first one was fixed in phosphate-buffer saline 
(PBS)-formalin solution, alcohol dehydrated and paraffin-embedded. Five µm sections were 
stained with hematoxilyn-eosin and Masson’s trichrome (Prophet & Arrington, 1992) for PA 
treated with bomocriptine. In each hematoxylin-eosin stained section was analyzed nuclear 
pleomorphism and mitosis figures. 
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2.2 Immunohistochemistry 
In other sections, immunohistochemistry (Bratthauer et al., 1994) was performed. Slides of 
each case were deparaffinized, rehydrated, and rinsed in PBS. Later on, endogenous 
peroxidase was blocked with 0.25 % H2O2/distilled water for 15 min., and blocking with 3% 
BSA in PBS (Albumin, Bovine, Sigma-AldrichCo. St. Louis USA). The slides were incubated 
for 1 h in ready to use monoclonal antibodies of pituitary hormones: prolactin, growth 
hormone (GH), luteinizing hormone (LH), follicle-stimulating hormone (FSH), thyroid 
stimulating hormone (TSH) (BioGenex, San Ramón, CA) and adrenocorticotropic hormone 
(ACTH, DAKO, Carpinteria, Ca, at a 1;100 dilution). Normal postmortem pituitaries were 
used as positive controls for pituitary hormones. To assess the proliferative index of 
pituitary adenomas Ki-67 antibody was used (Santa Cruz Biotechnology, inc. Santa Cruz 
CA. USA at 1:100 dilution). After that the sections were washed, and incubated for 30 min. 
with the secondary antibody (biotinylated anti-Ig, BioGenex, San Ramón, CA). After 
washing in PBS the sections were incubated for 30 min with peroxidase-conjugated 
streptavidina complex (BioGenex, San Ramón, CA).  The reaction was developed with 
diaminobenzidine (DAB) using a Dako kit detection system (Dako enVision System 
Peroxidase. Dako Carpinteria, CA) according to manufacturer’s instructions and the sections 
were hematoxylin counterstained. The immunodetection was analyzed under a wide-field 
microscope Olympus H2 (Tokyo, Japan). The immunoreactivity to different hormones in 
tumor cells were estimated as positive or negative, and the Ki-67 labeled index (LI) was 
assessed by counting the percentage of number of positive / nuclear cells in five 40x fields. 
Statistics analysis were done to associate Ki-67 labeling index (LI), disease evolution time, 
and outcome, in functional PA and in non-functional PA, hormone secretion, invasion 
degree, and tumor regrowth.  
2.3 Ultrastructural analysis 
The second part of biopsy was processed for its use in electron microscopy to assess the fine 
structure of PA. The tissues were fixed in 2.5% glutaraldehyde in 0.1 M phosphate-buffer-
saline (PBS pH 7.4) and postfixed in 1% tetroxide osmium in the same buffer, dehydrated in 
alcohol, and embedded in Epon. One-micron thick sections were stained with toluidine blue 
and examined by light microscopy. Ultrathin sections at the silver/grey area of the 
spectrum of interference colors were stained with uranyl acetate and lead citrate and 
examined under Zeiss EM 10 transmission electron microscopy. 
2.4 Statistical analysis 
Statistical analysis was performed by using the SPSS 13.0 software. ANOVA test and X2, 
Kurskal-Wallis were used to evaluate differences and association respectively, among 
evolution time and follow up with grades of invasion. Bivariate analysis was accomplished 
by means of Fisher’s exact test for association among functional and non-functional PA, or 
hormonal immunodetection with recurrences. U Mann-Whitney’s test was used to assess 
evolution time and follow up differences among functioning and non-functioning PA. To 
evaluate differences in Ki-67-LI detection among invasion grades, X2 Kurskal-Wallis test was 
done; among functioning and non-functioning PA with recurrences U Mann-Whitney’s test 
was used; and the association of Ki-67-LI detection with hormonal immunodetection, U 
Mann-Whitney’s test was accomplished. P value less than .05 were considered significant.  
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3. Results 
One hundred and twenty two pituitary adenomas were studied between 1988 and 1992. 
They were organized according to their characteristics, by means of transsphenoidal or 
transcranial-frontal technique, and the tumors were removed in 60 to 100%. Tumors mainly 
affected young adult population with a mean age of 41.4 yr. Sixty five (53.3%) were male, 
mean age of 43.6±14.8 yr (range, 17-71 yr) and 57 (46.7%) were female, mean age of 39.3±14.4 
yr (range, 13-75 yr). Twelve patients were under 20 yr (9.8%). Six males with mean age of 
18.8 ± 2.4 yr, and 6 females with mean age of 16.1 ± 2.5 yr. Clinically they were 11 
functioning PA and 1 non-functioning PA (Table 1). 
 
Grade Gender Age (yr) 
Evolution 
Time (yr) 
F NF Symptoms IHQ 
II M 17 1 X  Hypogonadism Prl 
II M 20 2 X  VA Ha Ac GH 
II F 23 4 X  VA Ha Am-Gal Prl-TSH 
II M 24 6 X  Cush Neg 
II M 18 4  X VA Ha Prl 
III F 14 2 X  VA Am Prl 
III M 20 8 X  Gal-Am Gig Prl-GH 
III F 23 8 X  VA Ha Am-Gal Prl-ACTH 
IV F 18 4 X  VA Ha Am Prl 
IV F 18 4 X  VA Ha Am-Gal Neg 
IV F 13 2 X  VA Am Prl 
IV M 20 2 X  VA Ac Prl-GH 
F= functioning pituitary adenoma; NF= non-functioning pituitary adenoma; VA= visual alterations; 
Ha= headache; Am= amenorrhea; Gal= Galactorrhea; Gig= gigantism; Ac= acromegaly; IHQ= 
immunohistochemical detection. 
Table 1. Pituitary adenomas in young cases under 20 years old at the onset of symptoms.  
The age column is the age at diagnosis.  
Twenty two cases (18%) were classified as I and II invasion grades tumors, and 66 cases 
(54.1%) were in extensive invasion phase (IV grade). The disease evolution time before the 
first surgery was 2.9±2.3 yr (range, 2 months to 10 years). Of the 122 patients thirty eight 
patients continued to attend their review appointments (31%). The average follow up time 
of the patients was 11±7.4 yr (range, 1-27 yr); from 1 to 5 yr, and from 15 to 20 yr, were the 
most frequent. Only one patient (0.8%) was considered healthy; four deaths have been 
reported. The remaining patients stopped coming to the Institute to control appointments. 
Thirty nine (31.9%) cases out of the 122 had recurrence; 23 (58.9%) belong to grade IV PA. In 
grade III and IV, two patients with recurrences were observed (Table 2). 
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Grade 
Cases 
n 
Gender 
Female n(%)
Mean Age
F/M 
Evolution Time
Years (mean) 
Follow up time
Years (range) 
Recurrences 
Cases n 
(%) 
1 2 
I 2 1 (50) 33/31 1.5 1 0   
II 20 4 (20%) 39/45 2.1 
10.6 
(1m-20yr) 
6 (15.3%) 6  
III 34 23 (67%) 40/34 3.4 
12.1 
(2-20) 
10 (25.6%) 7 3 
IV 66 29 (44%) 39/44 3 
10.3 
(1-27) 
23 (58.9%) 21 2 
Table 2. Pituitary adenomas classification by grades of invasion according to Hardy (1973). 
Disease evolution time, follow up time, and recurrences in each grade are shown. 
F= females; M= males; m= month. 
3.1 Immunohistochemistry 
Prolactin was the most frequent hormone detected by immunohistochemistry (54 cases, 
44.2%) (Table 3). Prolactin hormone expression was found in combination with others 
hormones: 10 were in combination with GH (8.1%), 4 (3.2%) with TSH; 3 (2.4%) with ACTH, 
and 1 (0.81%) with LH. Fifteen (12.3%) cases were positive for gonadotroph hormones, 5 
(4%) for growth hormone, 2 (1.6%) for ACTH, 1 (0.82%) for TSH, 1 (0.82%) multihormonal 
(HC-FSH-TSH), and 26 (21.3%) cases were negative for all hormones (Fig. 1). 
  
Fig. 1. Pituitary adenoma classification according to their hormonal content assessed by 
immunohistochemistry. 
Prolactin hormone expression was the most frequent detected. Prl= prolactin hormone; GH= 
Growth hormone; TSH= Thyroid stimulating hormone; ACTH= adrenocorticotropin 
hormone; LH= luteinizing hormone; FSH= follicle stimulating hormone; MH= 
multihormonal; Neg= negative. 
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Fig. 2. Classification of non-functioning pituitary adenomas. 
Immunohistochemical detection of hormonal expression in non-functioning pituitary 
adenomas. Prl= prolactin hormone; GH= Growth hormone; TSH= Thyroid stimulating 
hormone; ACTH= adrenocorticotropin hormone; LH= luteinizing hormone; FSH= follicle 
stimulating hormone; Neg= negative. 
There were 51 (41.8%) non-functioning PA, 17 (33%) were Prl positive by 
immunohistochemistry, 15 (29%) were negative, and 10 (19.6%) were positive for 
gonadotrophic hormones (Fig. 2).  
Non-functioning PA presented visual alterations and headache as clinical manifestations. 
There was 58.2% of clinically functioning pituitary adenomas. The most frequent clinical 
manifestations were:  amenorrhea, galactorrhea, and libido diminished. Acromegaly was 
found in GH positive pituitary adenomas and one patient with gigantism was found (Table 
1). Ki-67-LI was high in IV grade tumors (Table 3, Fig. 3).  
 
Grade Cases # F NF 
Prl 
# (%) 
Ki-67-LI 
Median (range) 
I 2 2 - 2 (100) ND 
II 20 10 10 11 (55) 10.7 (10-16) 
III 34 21 13 22 (64.7) 6.8 (1-20) 
IV 66 38 28 37 (56) 25.4 (2-35) 
Table 3. Pituitary adenomas classification according to their endocrine symptoms: Clinically 
functioning pituitary adenomas (F) and clinically non-functioning pituitary adenomas (NF). 
Prolactin hormone expression detected by immunohistochemistry (Prl). Number and 
percentage of positive cases, in each grade. Ki-67 Labeled Index (Ki-67-LI) in each grade. 
ND= No determined. 
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Fig. 3. Immunohistochemical detection 
Photomicrograph of pituitary adenomas stained with immunohistochemical technique. 
Antibodies against prolactin hormone (A), and Ki-67 (B). Prolactin detection is present in the 
cytoplasm and Ki-67 can be seen in nucleus. Arrows show the immunodetection. (original 
magnification X 400). 
3.2 Statistical analysis 
There was no significative statistic difference in disease evolution time (F=1.0, p=0.351) and 
follow up (F=0.1, p=0.885), compared between invasion degrees. Neither the evolution time 
(p=0.146) nor the follow-up time (p=0.678) differed between functioning PA and non-
functioning PA, however disease evolution time was lightly higher in III and IV invasion 
degrees. Evolution time (X2=2.4, p=0.287) and follow up time (X2=0.1, p=0.939) did not have 
association with the invasion grade.  
No association was found among recurrence and functioning PA (p=0.526), and with 
hormone immunodetection (Prl p=0.595; GH p=0.377; FSH p=0.635). 
Ki-67-LI was higher in IV grade (median value: 24.5%; range 2-35) in comparison with grade 
II (median value 6.8%; range 1-20; X2=6.4, p=0.029); Grade III PA has an intermediate value 
(median value 10.7%; range 10-16). There was no statistic difference of Ki-67-LI between 
functioning PA and non-functioning PA (p=0.893) or between PA with recurrence and PA 
without recurrence (p=0.253). There was no association of Ki-67-LI with hormone secretion 
type (Prl p=0.121; GH p=0.100; FSH p=0.5). 
3.3 Histopathological analysis  
Histologically 98.4% show high cellular density, discrete nuclear pleomorphism, and dense 
nuclei, between 7 and 10 µ of diameter (Fig. 4A). Neither necrosis areas nor mitotic figures 
were observed. Only two cases of IV grade invasion degree, which were prolactin secretor 
PA, show nuclear pleomorphism, pseudoinclusions, bi- or multinucleated cells, and mitotic 
figures (Fig. 4B and 4C). 
There were 11 prolactinomas (15.2%) treated with bromocriptine before surgery for a period 
of 2 months to 3 years. The drug decreased tumor size and serum prolactin levels, the 
menstruation was restored, galactorrhea stopped and fertility returned. Histologically 
interstitial fibroses was observed in these tumors (Fig. 4D). Ultrastructuraly the cells showed 
A B 
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smaller endoplasmic reticulum and Golgi complex; lysosomes were more frequent observed 
and there were scarce secretory granules. 
 
 
Fig. 4. Photomicrograph of pituitary adenomas with hematoxilyn-eosin stain (A-C), and 
with Masson’s trichrome stain for collagen fibers (D).  (A) PA showing solid pattern with 
homogeneous size cells. (B-C) PA showing nuclear pleomorphism (asterisk) and 
pseudoinclusions (arrow). (D) Bromocriptine treated PA which shows interstitial fibrosis 
(arrow). (Original magnification: X400). 
3.4 Ultrastructure 
3.4.1 Prolactin adenomas 
The most frequent type of pituitary adenomas was the prolactinoma (59%). All 
prolactinomas were sparsely granulated. The tumor show polyhedral cells with irregular 
nucleus, and prominent nucleolus. In the cytoplasm abundant, lamellar, rough endoplasmic 
reticulum and well development Golgi complex, was observed. There were scarce secretory 
granules, with size between 100-300 nm in diameter; some of them were localized between 
lateral cell surfaces which are known as misplaced exocytosis, the morphologic mark of 
prolactin secretor PA (Fig. 5). 
3.4.2 Growth hormone adenomas 
Adenoma secreting only growth hormone had an incidence of 4%. Ultrastructuraly this 
tumor was sparsely granulated. The cells showed pleomorphic and eccentric nucleus, with 
scarce and dilated endoplasmic reticulum. Fibrous bodies with type II filaments were 
A B 
C D 
*
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observed, some of them with secretory granules inside it, whose size was between 221 nm 
and up to 769 nm in diameter (Fig. 6A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Electronmicrographs of sparsely granulated prolactin adenoma grade II. (A) Lamellar 
endoplasmic reticulum (arrow). X 6,076; (B) fused secretory granules (black arrow) and 
misplaced exocytosis (white curved arrow). X9,750. Uranyl acetate-lead citrate. 
3.4.3 GH secreting adenoma and prolactin hormone adenoma 
Ten cases (8%) of pituitary adenomas with prolactin hormone and growth hormone 
secretion were found. Ultrastructuraly it was observed a monomorphous tumor, formed by 
only one cell type. All cells were scarcely granulated with secretory granules with 178 nm of 
diameter, few mitochondrias, lamellar endoplasmic reticulum and folded cell membranes;  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. Electronmicrograph of grade IV, GH PA, with their hall-mark fibrous body (arrow) 
X10,350. (A); grade III PA, prolactin and GH secreting, with lamellar endoplasmic reticulum 
(black arrow), crescent moon nuclei (curved arrow), and fibrous body of type II filaments 
(white arrow). X5,137. (B). Uranyl acetate-lead citrate. 
B A 
A B 
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nucleus show rounded or crescent moon shape in which concave area fibrous bodies were 
observed (Fig. 6B). 
3.4.4 Gonadotroph adenomas 
These adenomas were the most abundant (12%) after prolactinomas (44%) and the negative 
types for immunohistochemistry (21%).  This tumor was formed by polyhedral cells, with 
poorly developed cytoplasm. Nuclei had rounded contours, some of them with irregular 
shapes and eccentric nucleoli attached to the electron-dense perinuclear chromatin. Rough 
endoplasmic reticulum was scarce and dilated, and secretory granules were few and small 
(153 nm in diameter). Big Golgi complex was observed with dilated cisterns (Fig. 7A). In two 
IV grade cases, smooth endoplasmic reticulum, mixed with mitochondria and pleomorphic 
secretory granules were detected; there was a vacuolated Golgi complex which was 
arranged in a honey comb complex, the hall-mark of this adenoma type (Fig. 7B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7. Electronmicrograph of grade III gonadotroph PA. (A) This tumor showed big Golgi 
complex with dilated cisterns (arrow), small secretory granules located along the cell 
membrane (thin arrow). X 6,370; (B) Golgi shows a honey comb complex (arrow). X15,600. 
Uranyl acetate-lead citrate. 
3.4.5 Negative pituitary adenomas  
This type of tumors was negative for all hormones with the immunohistochemistry 
technique. Under transmission electron microscopy, poorly developed cells were observed 
with scarce rough endoplasmic reticulum, few secretory granules with 100-200 nm of 
diameter and small Golgi complex. In some cases it was observed numerous mitochondria, 
which is known as oncocytic transformation (Fig. 8A). 
3.4.6 Corticotroph adenoma 
There were 2 cases (1.6%) of ACTH secreting pituitary adenomas. This tumor showed 
polyhedral or elongated cells with poorly developed cytoplasm. The cell boundaries were 
clearly marked, elongated nuclei with irregular contours, and prominent nucleoli (8B); 
A B 
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secretory granules were scarce and small (104 nm). In one case proliferation of type I 
filaments were perceive with secretory granules inside it (Fig. 8C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8. (A) Electronmicrography of grade IV immunonegative PA.  This tumor showed 
sparsely granulated cells with abundant mitochondria (arrow). X9,900 ;  (B) Corticotroph 
cell adenoma grade III which consist of closely-apposed, angular cells, with marked cell 
boundaries (arrow), and nucleus with irregular shape (N). X6,370 ; (C) Cytoplasm with 
abundant type I filaments were observed (arrow). X8760. Uranyl acetate and lead citrate. 
4. Discussion 
Pituitary adenomas are heterogeneous tumors, this is because their different types of cells. 
The analysis of them had take into account several characteristic, the aim of these is to 
explain its behavior, although until now, has not been understood.  
Pituitary adenomas comprise nearly 15% of intracranial neoplasms and are the most common 
lesions in the sellar region (Valassi et al., 2010). There is a report of 84.6% PA in a study of 4,122 
tumors of sellar region (Saeger et al., 2007). In a 10-year study conducted at the National 
Institute of Neurology and Neurosurgery, in Mexico City, from 2,041 central nervous system 
tumors and covers, 26.2% were PA (personal communication). Here we present a study of 122 
case of PA which occurred between 13 and 75 yr old, with peak of incidence from 20 and 60 
years (100 cases; 81.9%), 10 yr earlier than other series (Davis et al., 2001). There was a slightly 
higher incidence in men; however women had earlier age at diagnosis (since 13 yr) than men 
(since 17), with higher frequency between 20 and 48 yr (men between 30 and 60 yr; 68%). 
Pituitary adenomas incidence are rare in young people under 20 yr and mostly are 
prolactinomas (86%) or corticotropinomas (10%) (Mindermann & Wilson, 1994). In this study  
was found 12 patients under 20 yr (9.8%); Nine (75%) were prolactinomas, one of which was 
Prl-ACTH positive, two Prl-GH, one Prl-TSH. From these 12 cases, one (8.3%) was GH 
immunopositive and in 2 PA the hormone expression was no detected. In table 1 it can be 
A 
B 
C 
N
www.intechopen.com
 Pituitary Adenomas 
 
60
observed, that in some patients the age at diagnosis (age column) is over 20 yr, although the 
patients reported that the beginning of the symptoms was some years before (evolution time). 
In general, tumor size correlates with functional activity (clinically functioning and clinically 
non-functioning pituitary adenomas), and in women has been observed that, prolactinomas 
and also in ACTH clinically functioning pituitary adenomas, the diagnosis is carry out at 
early stages. (Kontogeorgos, 2006). In our work we found 71 (58.1%) functioning PA; 44 
(61.9%) were in female of which only 5 (11%) were grade I and II PA and 39 (88.6%) were 
classified in III and IV grades. Out of this 39 PA, 29 (74%; 13 in grade III and 16 in grade IV) 
were prolactin immunopositive. In this case, women functioning adenomas, which 
produced prolactin hormone, were detected at an advance stage of invasion. 
In this study must of the PA were in a invasive phase (grade III and IV), and the disease 
evolution time in these patients was higher than in I and II grades, even though there was 
no statistical association with clinical manifestation (functioning or non-functioning PA) or 
hormonal activity assessed by immunohistochemistry. Similar long evolution time (from 10 
days to 20 years), has been reported in a Brazilian serie which was greater than the Italian 
and US series (Drange et al, 2000; Ferrante et al., 2006).   This may be due to the class of 
population that assist to this Institute, which are used to endure the symptoms of the disease 
for a long time before seeking medical treatment, or do not have the right information to 
perceive them at an early stage, also before turning to adequate health service they look for 
alternative therapies. As it has been suggested by other authors, the clinical signs might be 
underestimated or not correctly diagnosed (Drange et al., 2000; Ferrate et al., 2006). In our 
experience, patients as first choice went to the ophthalmologist, because of the visual 
alterations, and by the computed tomography or magnetic resonance imaging scans, sellar 
alterations were observed. Nowadays incidental detection of PA tumors has been increased 
due to radiological evaluations performed for unrelated reasons (Saeger et al., 2007). In this 
analysis we can observed that the functionality was not related to tumor size, but with time 
the patient will assit to the health center. 
Non-functioning pituitary adenomas are a diverse and heterogeneous group, where 
glycoprotein hormones, null cell adenoma and oncocytoma are included (Laws et al., 1982; 
Moreno et al., 2005). They are usually diagnosed as macroadenomas due to absence of 
clinical manifestations, which cause tumor growth in long time. Non-functioning PA 
account between 15% and 45% of pituitary tumors (Asa & Kovacs, 1992; Milker-Zabel et al., 
2005). It has been reported that 95-100% of non-functioning pituitary adenomas are 
macroadenomas, and the frequency of recurrence varies between 19% and 34.8% in different 
studies (Aurer & Clarici, 1985; Reddy et al., 2011); up to 79% has hormone expression, 
evaluated by immunohistochemistry (Moreno et al., 2005), being gonadotroph hormones 
and/or their ǂ- ǃ- subunits the most common (Cury et al., 2009, Hanson et al., 2005). In our 
study 51 (42%) tumors were non-functioning PA, of which 38 (74.5%) were men, this is 
consistent with other studies (Asa & Kovacs, 1992; Cury et al., 2009; Ferrante et al., 2006; 
Milker-Zabel et al., 2005). Out of 51 non-functioning pituitary adenomas, 15 (29.4%) showed 
recurrence and 41 (80%) were macroadenomas. In 71% of non-functioning PA hormone 
expression was found, being prolactin the most frequent hormone detected by 
immunohistochemistry (33%), followed by gonadotroph hormones (20%); there were 29% of 
immunonegative PA in accordance with Turner report (Turner et al., 1999). It is important to 
point out that 13 cases of non-functionig PA were female, 7 of grade III and 6 of grade IV. 
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There were no adenomas classified in grades I and II. In our case, in women non-
functioming pituitary adenomas could be related with the size.  
In pituitary adenomas recurrences are common problems. The large size and the invasive 
behavior of these tumors cause difficulties in their removal (Paek et al., 2005). It has been 
reported that about 50% of patients have tumor remnants, and tumor re-growth can be 
presented at 10 years after neurosurgery (Reddy, 2011; Sassolas et al., 1993). Generally larger 
tumors recurred more frequently than smaller adenomas after surgery (Gopalan et al., 2011; 
Saeger et al., 2007). In our work the tumors were removed between 60% and 100%, by means 
of transcranial-frontal or transsphenoidal technique, and in III and IV grades the recurrences 
were higher, with secondary recurrences in 5 patients (three in III grade and 2 in IV grade). 
The time of interval between surgery and recurrence ranged from 1 to 11 years in both 
clinically functioning PA and non-functioning PA. In non-functioning pituitary adenomas 
Reddy et al. (2011) showed relapse/re-growth in 10 or more years after the initial surgery, 
and found significant increase in re-growth rates when remnant pituitary tumors are 
observed on the first post-operative scan or if the patient is younger age at initial surgery.  
The follow up time of the patients is an important factor for their outcome (Dekkers et al., 
2008). In our work 38 (31%) patients were found  with  a mean of 11 yr of follow up (range 1-27 
yr),  12 of them were non-functioning PA with 10.3 yr of follow up (range, 1-27 yr). Reddy 
et.al. (Reddy, 2011) reports an average of 6.1 yr (range, 1-25.8) of follow up in 29 patients with  
non-functioning PA out of 155, of which 54 (34.8%) had recurrence, with 20% of relapse after 
10 years of surgery; they suggest that it is necessary to track patients beyond this time.  
In this study, few patients continued to attend for monitoring appointments. This could be 
because the patients who come to this health institution live outside of Mexico city, and 
sometimes it is difficult for them to travel to the city. Other patients are sent to other hospitals 
for continue their treatment, or they have no financial means for the follow up. Patients, who 
maintain their treatment and attendance to appointments for periodic reviews, have good 
outcome, with a improve of their visual impairments and hormonal levels, treated by 
hormonal substitution. It has been observed that patients with pre-operative anterior dysfunction 
recover function after surgery and the cases who presented with visual disturbance improve 
their vision with a second surgery (Chang et al., 2010; Müslüman et al., 2011). 
An important factor in the biological behavior of pituitary adenomas is their proliferative 
capacity, which could be assessed by counting mitoses and the immunostaining of nuclei for 
proliferation markers as Ki-67. Mitoses figures are rare in non-invasive pituitary adenomas 
(3.9% of cases), they are more frequent in invasive PA (21.4%) and are greater in carcinomas 
(66.7%) (Pernicope et al., 2001). In our study there were found 2 cases (1.6%) with mitoses, 
which is not different from that reported in other studies, including the recently established 
rare subtype spindle cell oncocytoma of the pituitary gland (Matyja et al., 2010; Saeger et al., 
2007). 
Ki-67 is the most important proliferation marker; it is expressed in early G1, S, G2, and M 
phases of the cell cycle. This marker is associated with tumor proliferation, invasiveness, 
and prognosis (Cattoretti et al., 1992; Petrowsky et al., 2001). In pituitary adenomas the 
value of Ki-67 is controversial, in relation to the aggressive behavior (de Aguiar et al., 2010; 
Zhao et al., 1999), and in pituitary carcinoma appear to predict rapid disease progression 
(Dudziak et al., 2011). In a study performed in 44 pituitary macroadenomas, visual field 
defect and recurrence show correlation with Ki-67 LI, no statistical differences were 
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observed in Ki-67 LI in relation to the Hardy´s classification (Paek et al., 2005). In other 
study in a series of 20 radically resected pituitary macroadenomas (11 functioning, 9 
nonfunctioning) MIB-1(antibody of Ki-67 antigen) did not show a significant difference of 
expression between recurrent and non-recurrent adenomas (Ruggeri et al., 2011). Yarman 
(2010) assessed Ki-67 expression in growth hormone-secreting pituitary adenomas and 
showed no correlation with the invasive character. In other study it has been observed that 
Ki-67 LI was marginally higher in clinically functioning adenomas than clinically non-
functioning adenomas. They also found significant difference in the MIB-1 LI in tumors with 
a maximum diameter of more than 4cm at a MIB-1 LI of ≥2%, however this difference was 
not statistically significant at a higher MIB-1 LI cut off value of >3% (Chacko et al., 2010). On 
the other hand, there is other report in which no significant difference in MIB-1 LI was 
found between functioning and non-functioning PA  (Scheithauer et al., 2006). In our results, 
Ki-67 LI was significantly higher in IV grade PA than those of II grade which is different to 
that reported by Paek (2005); however there was no statistic difference of Ki-67 LI between 
pituitary adenomas with recurrence or without recurrence. About functionality we did not 
found differences between functioning and non-functioning pituitary adenomas which 
differs with Scheithauer report (2006).  
Ultrastructural analysis of pituitary adenomas is an important tool for the detailed 
characterization of this type of tumors, particularly in problematic cases, because it is the 
initial basis of adenoma classification. With transmission electron microscopy it can be 
confirmed the endocrine nature of PA and their functional differentiation, which can be 
identified based on their ultrastructural markers of each hormonal type.  Despite the utility 
of electron microscopy analysis in the evaluation of these tumors, diagnostic cannot be 
made on ultrastructural grounds alone, it should be done taking into consideration 
histology, immunohistochemistry and electron microscopical morphologic features, as well 
as findings from imaging studies and the symptoms (Kontogeorgos, 2006). Both clinical and 
histopathological factors are important for the diagnostic and outcome of patients. 
In our study we observed the ultrastructural features of the different types of PA according 
to their hormonal expression, and in relation to clinical manifestations. Ultrastructural 
analysis was very useful in mixed secretory adenomas, as growth hormone and prolactin 
secreting PA where cells with fibrous bodies, hall-mark of GH pituitary adenoma. In this 
way, ultrastructural findings of most PA are consistent with the immunophenotype, 
however there are occasional cases with ultrastructural features less well differentiated like 
the rare carcinomas (Scheithauer et. al., 2001). 
5. Conclusion 
Pituitary adenomas are a heterogeneous group whose behavior has not been understood 
yet. In our study must of the tumors were in a extensive invasive phase, they affected young 
adult population and in this series of cases people under 20 years were founded. The disease 
evolution time and recurrence frequency was high in the advanced grades. The diagnosis of 
these tumors was not related with the clinical manifestations, according to the time taken by 
the patients to consult a doctor. The good outcome of patients depends on the follow-up, 
which has a very low rate for different reasons. 
Pituitary adenomas have benign histological aspect, however can be aggressive, and may 
have one or more recurrences, as has been shown in this analysis.  These neoplasms seem to 
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have, a natural evolution, a potential to invasion, sparing the nervous tissue and without 
seeding to distant organs. 
Although there are no parameters or experimental tests that serve as clear markers of disease 
progression, the data that have been obtained as a result of the evaluation of hormone 
expression and clinical evaluation, have important information that can be associated with 
pathogenicity of PA. Currently, there are new molecular techniques, as proteomic technique 
that allows us to investigate the proteins involved in the disease process. 
The setup of registry on pituitary tumours constitutes a useful tool to analyze clinical 
experience, improve therapeutic strategies and patient's care. It also contributes for teaching 
medical students and develops clinical research. 
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